

The TLI system can help day-3 single cleavage embryo transfer to obtain comparative clinical outcomes to day-4 or day-5

Research Article

Cite this article: Ji Y *et al.* (2024) The TLI system can help day-3 single cleavage embryo transfer to obtain comparative clinical outcomes to day-4 or day-5. *Zygote*. **32**: 230–235. doi: [10.1017/S0967199424000212](https://doi.org/10.1017/S0967199424000212)

Received: 8 September 2023

Revised: 11 April 2024

Accepted: 14 May 2024



Keywords:

blastocyst; cleavage; morula; pregnancy and perinatal outcome; single embryo transfer

Corresponding author: Shanshan Wang;

Email: wss_19860820@sina.com

Yue Ji and Linjun Chen contributed equally to this work.

Yue Ji^{1,2} , Linjun Chen^{1,2} , Fan Pan^{1,2}, Ruyu Jiang^{1,2} and Shanshan Wang^{1,2}

¹Center for Reproductive Medicine and Obstetrics and Gynecology, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, PR China and ²Center for Molecular Reproductive Medicine, Nanjing University, Nanjing, PR China

Summary

The aim was to explore whether the time-lapse imaging system can help day-3 single cleavage embryo transfer to obtain comparative clinical outcomes to day-4 or 5. The data of 1237 patients who underwent single embryo transfer from January 1, 2018, to September 30, 2020, in our reproductive medicine centre were retrospectively analysed. They were divided into the day-3 single cleavage-stage embryo transfer (SCT) group ($n = 357$), day-4 single morula transfer (SMT) group ($n = 129$) and day-5 single blastocyst transfer (SBT) group ($n = 751$) according to the different embryo transfer stage. The clinical and perinatal outcomes of the three groups were analysed and compared. The clinical pregnancy rates of the patients in the day-3 SCT group, day-4 SMT group and day-5 SBT group were 68.07, 70.54 and 72.04%, respectively. The live birth rates were 56.86, 61.24 and 60.99%, respectively. The monozygotic twin (MZT) rate in the day-3 SCT group was significantly lower than that in the day-5 SBT group ($P = 0.049$). Regarding perinatal outcomes, only the secondary sex ratio had a significant difference ($P < 0.05$). After age stratification, no improvement was found in the pregnancy outcomes of patients >35 years of age receiving blastocyst transfer. Our findings suggest that for patients with multiple high-quality embryos on day-3, prolonging the culture time can improve the pregnancy outcome to some extent, but it will bring risks. For centres that have established morphodynamic models, day-3 SCT can also achieve an ideal pregnancy outcome and reduce the rate of monozygotic twins and sex ratio.

Introduction

With the continuous development of assisted reproductive technology (ART), multiple pregnancy has become a notable problem, increasing the risk of maternal and neonatal complications (Mackie *et al.*, 2019; Ibiebele *et al.*, 2020). Multiple studies have shown that single embryo transfer (SET) has a significant effect on reducing the multiple pregnancy rate (Racca *et al.*, 2020; Mersereau *et al.*, 2017). In view of the high pregnancy rate of ART and the growing maturity of embryo culture and freezing technologies in China, individualized embryo transfer strategies have become the focus of how to further reduce the number of transferred embryos.

Throughout the development of ART, the transfer of two cleavage-stage embryos has been and continues to be the mainstream approach to stabilizing the pregnancy rate, resulting in a persistently high multiple pregnancy rate. The latest Chinese Society of Reproductive Medicine (CSRSM) data show that the multiple pregnancy rate of fresh cycles in China was up to 26.04% in 2019 (Zhang *et al.*, 2022). Based on the conventional morphological embryo selection method, day-3 single cleavage-stage embryo transfer (SCT) has a lower pregnancy rate (Glujovsky *et al.*, 2016). With progress in embryo culture technologies, blastocyst culture, a method for topping out embryos, can reduce the proportion of aneuploid embryos (Li *et al.*, 2021). Day-5 single blastocyst transfer (SBT), with the advantage of a higher implantation rate, can effectively reduce the multiple pregnancy rate (Marconi *et al.*, 2022) and thereby become the main direction of current SET; however, it may also lead to an increased cycle cancellation rate, a lower embryo utilization rate, sex-ratio imbalance and other risks (Spangmose *et al.*, 2020).

At present, the choice of a single SET stage is still inconclusive for patients with multiple good-quality cleavage-stage embryos on day 3 in the fresh cycle. Therefore, this article presents a retrospective analysis of the pregnancy and perinatal outcomes of day-3 SCT, day-4 SMT and day-5 SBT in fresh cycles in our centre and further explores how to select an individualized embryo transfer strategy while seeking to balance live birth from a single transfer cycle with multiple pregnancy, thereby providing clinical guidance.

© The Author(s), 2024. Published by Cambridge University Press.

Material and methods

Patient selection

The data of patients who underwent *in vitro* fertilization and embryo transfer (IVF-ET) in our reproductive medicine centre from January 1, 2018, to September 30, 2020, were retrospectively analysed.

The inclusion criteria were as follows: ① Maternal age ≤ 40 years; ② Number of cycles ≤ 2 ; ③ Number of oocytes retrieved = 5–20; ④ Number of 2PN-derived grade I embryos with 8–10 cells on Day-3 ≥ 4 ; ⑤ Underwent SET; ⑥ Endometrial thickness ≥ 8 mm. The exclusion criteria were as follows: ① Combined with chromosome abnormality, endometriosis, uterine leiomyoma, immune infertility or other diseases that affect embryo implantation; ② Preimplantation genetic testing or oocyte donation cycle; ③ Systemic disease, etc.

Controlled ovarian stimulation and oocyte harvest

The routine practice of our centre was followed. The starting dose of gonadotropin was selected according to the patient's age, basal follicle-stimulating hormone (FSH) level, body mass index (BMI) and antral follicle count. In the presence of at least 1 ovarian follicle ≥ 18 mm, 10,000 IU human chorionic gonadotropin (HCG) (Serono, Switzerland) or 250 μg recombinant human chorionic gonadotropin alfa for injection (Ovidrel, Serono, Switzerland) was administered as the trigger. Oocytes were retrieved through paracentesis as directed by vaginal ultrasound at 36–38 h after injection, and then the harvested oocytes were washed in Gamete medium (Vitrolife, Sweden) and transferred into IVF medium (Vitrolife, Sweden) for subsequent fertilization.

Fertilization and embryo culture

Conventional IVF fertilization was performed in the form of short-term fertilization after the retrieved oocytes were cultured *in vitro* for 3 h; namely, the oocytes and sperm were mixed at a 1:10000 ratio and incubated for 5 h to denude the cumulus cells. After the fertilization was judged as successful based on the release of the second polar body, the fertilized eggs were transferred to a time-lapse imaging petri dish containing G1 cleavage-stage medium (Vitrolife, Sweden) and cultured in the Embryoscope time-lapse imaging (TLI) system (Vitrolife, Sweden). For patients suitable for intracytoplasmic sperm injection (ICSI), cumulus cells were denuded 2 h after oocyte retrieval, after which the mature oocytes were subjected to ICSI and transferred to a TLI petri dish with G1 cleavage-stage medium (Vitrolife, Sweden). Pronuclei were observed 16–20 h after fertilization, and the presence of double pronuclei (2PN) and two polar bodies (2PB) indicated normal fertilization. On day-3 after oocyte retrieval, except for the embryos to be transferred and frozen, the remaining embryos were transferred to the same position of a petri dish containing G2 blastocyst medium (Vitrolife, Sweden) and cultured until the end of day-6.

Embryo assessment

The scores of cleavage-stage embryos were assessed from the cell number, fragmentation and homogeneity according to the Alpha/ESHRE consensus (2011) (Alpha Scientists in Reproductive Medicine and ESHRE Special Interest Group of Embryology, 2011) using the stratified screening model established by our centre based on the TLI system. The morulae and blastocysts were

assessed according to the Gardner scoring criteria (Gardner and Schoolcraft, 1999). The definition of the top-quality embryo was 2PN-derived grade I embryos with 8–10 cells on day-3.

Embryo transfer (ET) and pregnancy determination

SET was performed by selecting top-quality cleavage-stage embryos, morulae or blastocysts on day-3, day-4 or day-5 after oocyte retrieval. Progesterone gel (Merck Serono, Switzerland) was routinely administered at the vagina as luteal phase support after transfer, and the blood HCG value was determined 2 weeks later. A diagnosis of biochemical pregnancy was made when HCG was ≥ 40 U/L. Clinical pregnancy was defined as the presence of a gestation sac(s) on ultrasound at 4–6 weeks after ET. Early spontaneous miscarriage was defined as spontaneous miscarriage occurring within 12 weeks of clinical pregnancy.

Statistical analysis

SPSS 25.0 was used for analysis and statistics. The measurement data are expressed as the mean \pm standard deviation ($\bar{x} \pm s$), and the samples of the three groups were compared by analysis of variance. The enumeration data are expressed as the constituent ratio or rate and were compared by means of the chi-square test or Fisher's precision probability test. The dichotomous logistic regression model was adopted for multivariate analysis. $P < 0.05$ indicated that the difference was statistically significant.

Results

As shown in Table 1, there were no significant differences in maternal age, BMI, infertility years, infertility factors, basal FSH, basal luteinizing hormone (LH), endometrial thickness on embryo transfer day or proportion of ICSI cycles among the three groups ($P > 0.05$). However, there were significant differences in the number of oocytes retrieved and estradiol level on the trigger day ($P < 0.05$), which were smaller in the day-3 SCT group than in the day-4 SMT and day-5 SBT groups.

Comparison of pregnancy and perinatal outcomes

As shown in Table 2 and Table 3, there were no significant differences in the clinical pregnancy rate, miscarriage rate, ectopic pregnancy rate, live birth rate, premature birth rate, gestational age, newborn weight, body height or birth defects among the three groups ($P > 0.05$). The monozygotic twin (MZT) rate of day-3 SCT was significantly lower than that of day-5 SBT ($P < 0.05$). The day-5 SBT group had a significantly higher proportion of newborn boys than the day-3 SCT group ($P < 0.05$).

The influence of confounding factors on SET pregnancy

As shown in Table 4, maternal age had significant effects on the clinical pregnancy rate and live birth rate of SET ($P < 0.05$). Basal FSH, basal LH, BMI, endometrial thickness on embryo transfer day, number of oocytes retrieved and period of embryo transfer had no significant effect on the clinical pregnancy rate and live birth rate of SET ($P > 0.05$).

Clinical outcomes after age stratification

There were no significant differences in the clinical pregnancy rate and live birth rate of patients < 35 years of age among the three groups (Figures 1, 2). Patients > 35 years of age in the day-5 SBT

Table 1. Maternal and cycle characteristics among the different groups

	Day-3 SCT	Day-4 SMT	Day-5 SBT	P-value
Number of cycles	357	129	751	-
Age (years)	29.99 ± 3.89	29.73 ± 3.28	29.76 ± 3.51	0.627
BMI (kg/m ²)	22.87 ± 3.18	22.94 ± 3.48	22.87 ± 3.29	0.975
Duration of infertility (years)	3.12 ± 2.06	3.01 ± 1.87	3.13 ± 2.24	0.834
Infertility factors				
Male factor	38 (10.64) ^a	10 (7.75)	70 (9.32)	0.599
Pelvic fallopian tube factor	270 (75.63)	95 (73.64)	559 (74.43)	0.875
Ovulatory dysfunction	421 (11.76)	21 (16.28)	106 (14.11)	0.374
Unexplained factors	7 (1.96)	3 (2.33)	16 (2.13)	0.915
Basal FSH (IU/L)	7.56 ± 1.77	7.21 ± 1.66	7.36 ± 1.81	0.105
Basal LH (IU/L)	5.81 ± 3.58	6.59 ± 3.80	5.99 ± 4.07	0.160
Estradiol level on the trigger day	2484.44 ± 1339.87	3272.73 ± 1529.90	3072.52 ± 1542.58	<0.001
Number of oocyte retrieval	12.64 ± 3.38	13.54 ± 3.67	13.83 ± 3.14	<0.001
Insemination method				
IVF	293 (82.07)	103 (79.84)	637 (84.82)	0.255
ICSI	64 (17.93)	26 (20.16)	114 (15.18)	-
Endometrial thickness (mm)	11.95 ± 2.45	11.91 ± 2.42	11.81 ± 2.42	0.640

^aValues in parenthesis are expressed in percentage.

SCT = single cleavage-stage embryo transfer; SMT = single morula transfer; SBT = single blastocyst transfer; BMI = body mass index; FSH = follicle-stimulating hormone; LH = luteinizing hormone; IVF = *in vitro* fertilization; ICSI = intracytoplasmic sperm injection.

Table 2. Clinical pregnancy outcomes among the three groups

	Day-3 SCT	Day-4 SMT	Day-5 SBT	P-value
Number of cycles	357	129	751	-
Number of clinical pregnancy	243 (68.07) ^a	91 (70.54)	541 (72.04)	0.398
Number of miscarriage	36 (14.81)	12 (13.19)	76 (14.05)	0.922
Number of ectopic pregnancy	4 (1.65)	0	5 (0.92)	0.470
Number of monozygotic twins	5 (2.06)	5 (5.49)	32 (5.91)	0.049
Number of live births	203 (56.86)	79 (61.24)	458 (60.99)	0.400

^aValues in parenthesis are expressed in percentage.

SCT = single cleavage-stage embryo transfer; SMT = single morula transfer; SBT = single blastocyst transfer.

Table 3. Neonatal outcomes among the three groups

	Day-3 SCT	Day-4 SMT	Day-5 SBT	P-value
Number of live births	203	79	458	-
Boys	97 (47.78) ^a	45 (56.96)	274 (59.83)	0.016
Girls	106 (52.22)	34 (43.04)	184 (40.17)	-
Number of preterm birth	17 (8.37)	10 (12.66)	48 (10.43)	0.524
Gestational age (weeks)	38.32 ± 1.91	38.26 ± 2.04	38.34 ± 1.81	0.901
Birthweight (g)	3266.58 ± 547.76	3218.54 ± 506.73	3283.50 ± 555.94	0.615
Height (cm)	49.76 ± 1.86	49.74 ± 2.27	49.87 ± 2.09	0.768
Number of birth defects	3 (1.48)	2 (2.53)	7 (1.52)	0.749

^aValues in parenthesis are expressed in percentage.

SCT = single cleavage-stage embryo transfer; SMT = single morula transfer; SBT = single blastocyst transfer.

Table 4. Multivariate analysis of clinical pregnancy and live birth rates according to maternal and cycle characteristics

	Clinical pregnancy rate		Live birth rate	
	OR (95% CI)	P-value	OR (95% CI)	P-value
Age	0.953 (0.920–0.987)	0.008	0.946 (0.916–0.978)	0.001
Basal FSH	0.979 (0.911–1.053)	0.569	0.995 (0.931–1.065)	0.890
Basal LH	1.022 (0.988–1.057)	0.216	1.010 (0.980–1.041)	0.498
BMI	1.003 (0.965–1.043)	0.872	0.994 (0.958–1.030)	0.727
Endometrial thickness	1.032 (0.980–1.087)	0.226	1.039 (0.991–1.090)	0.116
Number of oocyte retrieval	1.009 (0.971–1.049)	0.642	1.011 (0.975–1.048)	0.555
Stage of embryo transfer	1	–	1	–
Day-3 SCT	0.846 (0.640–1.119)	0.242	0.862 (0.664–1.120)	0.266
Day-4 SMT	0.898 (0.593–1.359)	0.610	0.988 (0.670–1.455)	0.949
Day-5 SBT				

OR = odds ratio; CI = confidence interval; FSH = follicle-stimulating hormone; LH = luteinizing hormone; BMI = body mass index; SCT = single cleavage-stage embryo transfer; SMT = single morula transfer; SBT = single blastocyst transfer.




Figure 1. Clinical pregnancy rate among the three groups according to female age.




Figure 2. Live birth rate among the three groups according to female age.

group showed a downward trend in the clinical pregnancy and live birth rates, but the differences were not significant (Figures 1, 2).

Discussion

The results of this study showed that no significant difference was found in the clinical pregnancy rate, miscarriage rate, ectopic pregnancy rate or live birth rate among the three groups. The MZT rate in the day-3 SCT group was significantly lower than that in the

day-5 SBT group. The proportion of newborn boys in the day-5 SBT group was significantly higher than that in the day-3 SCT group. With the help of the TLI system, day-3 SCT can obtain comparative clinical outcomes to day-4 or 5 while reducing the risks of MZT and gender imbalance.

In terms of pregnancy outcomes, multiple studies have reported that the implantation rate of blastocyst transfer is significantly higher than that of cleavage-stage embryo transfer (Yang *et al.*, 2018; Zeng *et al.*, 2018). This may be attributed to the fact that

some aneuploid embryos and embryos with poor developmental potential were eliminated by the blastocyst culture process. In addition, blastocyst embryo transfer can improve uterine/embryonic synchronicity (Neuhauss *et al.*, 2020). According to the results of this study, the clinical pregnancy and live birth rates of day-5 SBT were higher than those of day-3 SCT, but there were no significant differences, which might be attributed to the use of the TLI system and morphodynamic models. In this study, the pregnancy outcomes of day-5 SBT were similar to those of day-4 SMT and slightly higher than those of day-3 SCT, which is consistent with the study findings of Li *et al.* (2018). After embryo densification, the silent genome is activated, resulting in a reduction in morula-stage chimeric embryos (Vassena *et al.*, 2011). In addition, day-4 is closer to the window phase of the endometrium than day-3, so the day-4 strategy is more flexible. However, the current scoring criteria for morula are still immature, imposing certain limitations on their actual clinical application.

The choice of embryos for transfer plays an essential role in the success of SET. Our centre established a mature stratified screening model using time-lapse imaging technology on day-3 and applied it to day-3 SCT, leading to a stable implantation rate above 60% (Wang *et al.*, 2019), which might avoid the risk that patients cancel cycles due to concerns about the lack of embryos available for transfer.

The data of multiple large-sample-size studies showed that patient age is a factor directly affecting the implantation rate (Cimadomo *et al.*, 2018), and subsequent analysis was performed with age stratification. In this study, for younger patients (<30 years of age and 31–35 years of age), day-5 SBT achieved higher clinical pregnancy and live birth rates than day-3 SCT, although this result was not significantly different. For older patients (36–40 years of age), the clinical pregnancy and live birth rates of day-5 SBT were lower than those of day-3 SCT, and blastocyst transfer did not improve the pregnancy outcomes of this population but increased the risk of cancelling embryo transfer (Chen *et al.*, 2018). In a prior randomized controlled trial (RCT) (Papanikolaou *et al.*, 2006), in young patients <36 years of age, the pregnancy and live birth rates of SBT were significantly higher than those of SCT, but the population >36 years of age was not studied. Multiple guidelines, including those of the ASRM (Practice Committee of the American Society for Reproductive Medicine 2017), also recommend <35 years as the age for receiving elective SET. However, some studies have also shown that the effect of maternal age on the pregnancy rate will decrease after the embryos develop to the blastocyst stage (Maheshwari *et al.*, 2011), and blastocyst culture and transfer could significantly increase the pregnancy rate per embryo transfer cycle and might be appropriate in some older patients with a good clinical prognosis (Sainte-Rose *et al.*, 2021).

The secondary sex ratio is generally defined as the ratio of males to females at live births. In this study, the results showed that the proportion of newborn boys in the day-5 SBT group was significantly higher than that in the day-3 SCT group, which is consistent with the meta-analysis results from 18 reproductive medicine centres (Bu *et al.*, 2014). Luke *et al.* (2009) found that male embryos develop faster than female embryos, which makes them more likely to be selected for transfer. According to the study conducted by Maalouf *et al.* (2014), the genes controlling glucose uptake and metabolism (glucose-6-phosphate dehydrogenase) and antioxidants (hypoxanthine phosphoribosyl transferase) are located on the X chromosome, and the second X chromosome exists only in females; thus, female embryos have higher glucose uptake and detoxification of oxygen radicals, and potentially, the double dose of enzyme activity can explain the delayed

development of female embryos. In addition, a study reported that trophoblast grade is also correlated with the sex ratio (Lou *et al.*, 2020), and male embryos with more trophoblasts are morphologically more likely to be selected for transfer. However, there are also some reports that blastocyst transfer will not significantly increase the sex ratio, and the reason for such an inconsistency may be that ICSI technology decreases the proportion of male babies, which offsets the effect of blastocyst transfer on increasing the sex ratio (Wang *et al.*, 2020).

MZT is a serious complication of ART, and in this study, the MZT rate of day-5 SBT was significantly higher than that of day-3 SCT. A meta-analysis by Busnelli *et al.* (2018) showed that extended *in vitro* culture may increase the MZT rate. The possible mechanism is that extended *in vitro* culture may stimulate the splitting of the inner cell mass and affect cell-to-cell adhesion.

In summary, for patients with multiple good-quality embryos on day-3, prolonging the culture time can improve the clinical pregnancy and live birth rates but may bring risks of gender imbalance and increased monozygotic twin rates. For day-3 SCT, each centre should establish a kinetic parameter model based on a suitable embryo screening system, which can also achieve satisfactory pregnancy outcomes and further benefit people with fewer good-quality embryos on day-3 and older patients. In the future, further expansion of the sample size and multicentre RCTs should be conducted to continuously optimize individualized embryo transfer strategies, stabilize the implantation rate, effectively reduce the multiple pregnancy rate and guarantee the safety of mothers and babies.

Data availability statement. The dataset generated for this study are available on request to the corresponding author.

Acknowledgements. We thank all our patients without whom this work would have been impossible.

Funding. Not applicable.

Competing interests. The authors have no relevant financial or non-financial interests to disclose.

Ethical standards. The Ethics Committee of Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, approved this study (No. 2021–151). Informed consent was received from all enrolled patients.

References

- Alpha Scientists in Reproductive Medicine and ESHRE Special Interest Group of Embryology.** (2011). The Istanbul consensus workshop on embryo assessment: proceedings of an expert meeting. *Human Reproduction* 26(6), 1270–1283. <https://doi.org/10.1093/humrep/der037>.
- Bu, Z., Chen, Z.J., Huang, G., Zhang, H., Wu, Q., Ma, Y., Shi, J., Xu, Y., Zhang, S., Zhang, C., Zhao, X., Zhang, B., Huang, Y., Sun, Z., Kang, Y., Wu, R., Wu, X., Sun, H. and Sun, Y. (2014). Live birth sex ratio after in vitro fertilization. and embryo transfer in China—an analysis of 121,247 babies from 18 centers. *PLoS One* 9(11), e113522. <https://doi.org/10.1371/journal.pone.0113522>.
- Busnelli, A., Dallagiovanna, C., Reschini, M., Paffoni, A., Fedele, L. and Somigliana, E. (2018). Risk factors for monozygotic twinning after in vitro fertilization: a systematic review and meta-analysis. *Fertility Sterility* 111(2), 302–317. <https://doi.org/10.1016/j.fertnstert.2018.10.025>.
- Chen P, Li T, Jia L, Fang C and Liang X. (2018). Should all embryos be cultured to blastocyst for advanced maternal age women with low ovarian reserve: a single center retrospective study. *Gynecology Endocrinology* 34(9), 761–765. <https://doi.org/10.1080/09513590.2018.1450379>.

- Cimadomo, D., Fabozzi, G., Vaiarelli, A., Ubaldi, N., Ubaldi, F.M. and Rienzi, L. (2018). Impact of maternal age on oocyte and embryo competence. *Frontiers in Endocrinology (Lausanne)* 9, 327. <https://doi.org/10.3389/fendo.2018.00327>.
- Gardner, D.K. and Schoolcraft, W.B. (1999). Culture and transfer of human blastocysts. *Current Opinion in Obstetrics and Gynecology* 11(3), 307–311. <https://doi.org/10.1097/00001703-199906000-00013>.
- Glujovsky, D., Farquhar, C., Quinteiro Retamar, A.M., Alvarez Sedo, C.R. and Blake, D. (2016). Cleavage stage versus blastocyst stage embryo transfer in assisted reproductive technology. *Cochrane Database Systematic Reviews* 6, CD002118. <https://doi.org/10.1002/14651858.CD002118.pub5>.
- Ibibebe, I., Humphries, J.B., Torvaldsen, S., Ford, J.B., Morris, J.M., Bowen, J.R. and Randall, D.A. (2020). Gestational age, morbidity and mortality among twin births in New South Wales, Australia 2003–2014: a cohort study. *Australian and New Zealand Journal of Obstetrics and Gynaecology* 60(4), 541–547. <https://doi.org/10.1111/ajo.13101>.
- Li, R.S., Hwu, Y.M., Lee, R.K., Li, S.H. and Lin, M.H. (2018). Day 4 good morula embryo transfer provided compatible live birth rate with day 5 blastocyst embryo in fresh IVF/ET cycles. *Taiwan Journal of Obstetrics and Gynecology* 57(1), 52–57. <https://doi.org/10.1016/j.tjog.2017.12.008>.
- Li, Y., Liu, S. and Lv, Q. (2021). Single blastocyst stage versus single cleavage stage embryo transfer following fresh transfer: a systematic review and meta-analysis. *European Journal of Obstetrics and Gynecology and Reproductive Biology* 267, 11–17. <https://doi.org/10.1016/j.ejogrb.2021.10.004>.
- Lou, H., Li, N., Zhang, X., Sun, L., Wang, X., Hao, D. and Cui, S. (2020). Does the sex ratio of singleton births after frozen single blastocyst transfer differ in relation to blastocyst development? *Reproductive Biology and Endocrinology* 18(1), 72. <https://doi.org/10.1186/s12958-020-00623-x>.
- Luke, B., Brown, M.B., Grainger, D.A., Baker, V.L., Ginsburg, E. and Stern, J.E. (2009). Society for Assisted Reproductive Technology Writing Group. The sex ratio of singleton offspring in assisted-conception pregnancies. *Fertility Sterility* 92(5), 1579–1585. <https://doi.org/10.1016/j.fertnstert.2008.08.107>.
- Maalouf, W.E., Mincheva, M.N., Campbell, B.K. and Hardy, I.C. (2014). Effects of assisted reproductive technologies on human sex ratio at birth. *Fertility Sterility* 101(5), 1321–1325. <https://doi.org/10.1016/j.fertnstert.2014.01.041>.
- Mackie, F.L., Rigby, A., Morris, R.K. and Kilby, M.D. (2019). Prognosis of the co-twin following spontaneous. Single intrauterine fetal death in twin pregnancies: a systematic review and meta-analysis. *BJOG* 126(5), 569–578. <https://doi.org/10.1111/1471-0528.15530>.
- Maheshwari, A., Griffiths, S. and Bhattacharya, S. (2011). Global variations in the uptake of single embryo transfer. *Human Reproduction Update* 17(1), 107–120. <https://doi.org/10.1093/humupd/dmq028>.
- Marconi, N., Allen, C.P., Bhattacharya, S. and Maheshwari, A. (2022). Obstetric and perinatal outcomes of singleton pregnancies after blastocyst-stage embryo transfer compared with those after cleavage-stage embryo transfer: a systematic review and cumulative meta-analysis. *Human Reproduction Update* 28(2), 255–281. <https://doi.org/10.1093/humupd/dmab042>.
- Mersereau, J., Stanhiser, J., Coddington, C., Jones, T., Luke, B. and Brown, M.B. (2017). Patient and cycle. Characteristics predicting high pregnancy rates with single-embryo transfer: an analysis of the Society for Assisted Reproductive Technology outcomes between 2004 and 2013. *Fertility Sterility* 108(5), 750–756. <https://doi.org/10.1016/j.fertnstert.2017.07.1167>.
- Neuhauser, W.M., Vaughan, D.A., Sakkas, D., Hacker, M.R., Toth, T. and Penzias, A. (2020). Non-inferiority of cleavage-stage versus blastocyst-stage embryo transfer in poor prognosis IVF patients (PRECiSE trial): study protocol for a randomized controlled trial. *Reproductive Health* 17(1), 16. <https://doi.org/10.1186/s12978-020-0870-y>.
- Papanikolaou, E.G., Camus, M., Kolibianakis, E.M., Van Landuyt, L., Van Steirteghem, A. and Devroey, P. (2006). In vitro fertilization with single blastocyst-stage versus single cleavage-stage embryos. *New England Journal of Medicine* 354(11), 1139–1146. <https://doi.org/10.1056/NEJMoa0535247>.
- Practice Committee of the American Society for Reproductive Medicine. Electronic address: ASRM@asrm.org; Practice Committee of the Society for Assisted Reproductive Technology. (2017). Guidance on the limits to the number of embryos to transfer: a committee opinion. *Fertility Sterility* 107(4), 901–903. <https://doi.org/10.1016/j.fertnstert.2017.02.107>.
- Racca, A., Drakopoulos, P., Van Landuyt, L., Willem, C., Santos-Ribeiro, S., Tournaye, H., Blockeel, C. and Polyzos, N.P. (2020). Single and double embryo transfer provide similar live birth rates in frozen cycles. *Gynecology Endocrinology* 36(9), 824–828. <https://doi.org/10.1080/09513590.2020.1712697>.
- Sainte-Rose, R., Petit, C., Dijols, L., Frapsauce, C. and Guerif, F. (2021). Extended embryo culture is effective for patients of an advanced maternal age. *Science Reproduction* 11(1), 13499. <https://doi.org/10.1038/s41598-021-92902-9>.
- Spangmose, A.L., Ginström Ernstad, E., Malchau, S., Forman, J., Tiitinen, A., Gissler, M., Opdahl, S., Romundstad, L.B., Bergh, C., Wennerholm, U.B., Henningsen, A.A. and Pinborg, A. (2020). Obstetric and perinatal risks in 4601 singletons and 884 twins conceived after fresh blastocyst transfers: a Nordic study from the CoNARTaS group. *Human Reproduction* 35(4), 805–815. <https://doi.org/10.1093/humrep/deaa032>.
- Vassena, R., Boué, S., González-Roca, E., Aran, B., Auer, H., Veiga, A. and Izpisua Belmonte, J.C. (2011). Waves of early transcriptional activation and pluripotency program initiation during human preimplantation development. *Development* 138(17), 3699–3709. <https://doi.org/10.1242/dev.064741>.
- Wang, M., Liu, X., Zhang, H., Li, L., Liu, R., Zhang, H. and Yu, Y. (2020). Associated factors of secondary sex ratio of offspring in assisted reproductive technology: a cross-sectional study in Jilin Province, China. *BMC Pregnancy Childbirth* 20(1), 666. <https://doi.org/10.1186/s12884-020-03373-1>.
- Wang, S., Chen, L., Fang, J., Jiang, W. and Zhang, N. (2019). Comparison of the pregnancy and obstetric. Outcomes between single cleavage-stage embryo transfer and single blastocyst transfer by time-lapse selection of embryos. *Gynecology Endocrinology* 5(9), 792–795. <https://doi.org/10.1080/09513590.2019.1594762>.
- Yang, L., Cai, S., Zhang, S., Kong, X., Gu, Y., Lu, C., Dai, J., Gong, F., Lu, G. and Lin, G. (2018). Single embryo transfer by Day 3 time-lapse. Selection versus Day 5 conventional morphological selection: a randomized, open-label, non-inferiority trial. *Human Reproduction* 33(5), 869–876. <https://doi.org/10.1093/humrep/dey047>.
- Zeng, M., Su, S. and Li, L. (2018). Comparison of pregnancy outcomes after vitrification at the cleavage and blastocyst stage: a meta-analysis. *Journal of Assisted Reproduction and Genetics* 35(1), 127–134. <https://doi.org/10.1007/s10815-017-1040-1>.
- Zhang, X., Deng, C., Huang, X., Liu, P., Zhou, C., Feng, Y., Hao, G., Lu, W., Quan, S., Shen, H., et al. (2022). Annual report on assisted reproductive technology of Chinese Society of Reproductive Medicine in 2019. *Journal of Reproductive Medicine* 31(8), 1015–1021. <https://doi.org/10.3969/j.issn.1004-3845.2022.08.001>.